Peptide 74 | CAS#132116-39-3 | synthetic peptide

MedKoo Cat#: 596901 | Name: Peptide 74

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Peptide 74 is a synthetic peptide that contains the sequence immediately upstream of the cleavage site of the 72-kDa type IV collagenase and other members of the matrix metalloproteinase family; inhibits the activated form of this enzyme.

Chemical Structure

Peptide 74

CAS#132116-39-3

Theoretical Analysis

MedKoo Cat#: 596901

Name: Peptide 74

CAS#: 132116-39-3

Chemical Formula: C62H107N23O20S2

Exact Mass: 1557.7504

Molecular Weight: 1558.79

Elemental Analysis: C, 47.77; H, 6.92; N, 20.67; O, 20.53; S, 4.11

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Peptide 74; Thr-met-arg-lys-pro-arg-cys-gly-asn-pro-asp-val-ala-asn;

IUPAC/Chemical Name

Threonyl-methionyl-arginyl-lysyl-prolyl-arginyl-cysteinyl-glycyl-asparaginyl-prolyl-aspartyl-valyl-alanyl-asparagine

InChi Key

DAZBILQQVFBVPE-XKKUQSFHSA-N

InChi Code

InChI=1S/C62H107N23O20S2/c1-29(2)47(57(101)74-30(3)48(92)81-38(60(104)105)25-43(65)88)83-53(97)36(26-45(90)91)80-55(99)41-16-11-22-85(41)59(103)37(24-42(64)87)75-44(89)27-73-49(93)39(28-106)82-51(95)33(14-9-20-72-62(69)70)77-54(98)40-15-10-21-84(40)58(102)35(12-6-7-18-63)79-50(94)32(13-8-19-71-61(67)68)76-52(96)34(17-23-107-5)78-56(100)46(66)31(4)86/h29-41,46-47,86,106H,6-28,63,66H2,1-5H3,(H2,64,87)(H2,65,88)(H,73,93)(H,74,101)(H,75,89)(H,76,96)(H,77,98)(H,78,100)(H,79,94)(H,80,99)(H,81,92)(H,82,95)(H,83,97)(H,90,91)(H,104,105)(H4,67,68,71)(H4,69,70,72)/t30-,31+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,46-,47-/m0/s1

SMILES Code

NC(NCCC[C@@H](C(N[C@@H](CS)C(NCC(N[C@@H](CC(N)=O)C(N1CCC[C@H]1C(N[C@@H](CC(O)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CC(N)=O)=O)C)=O)C(C)C)=O)=O)=O)=O)=O)=O)NC([C@@H]2CCCN2C([C@H](CCCCN)NC([C@@H](NC([C@@H](NC([C@@H](N)[C@H](O)C)=O)CCSC)=O)CCCNC(N)=N)=O)=O)=O)=N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,558.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Infantino M, Meacci F, Grossi V, Benucci M, Morozzi G, Tonutti E, Tampoia M, Ott A, Meyer W, Atzeni F, Sarzi-Puttini P, Manfredi M, Bizzaro N. Serological epitope profile of anti-Ro52-positive patients with systemic autoimmune rheumatic diseases. Arthritis Res Ther. 2015 Dec 17;17:365. doi: 10.1186/s13075-015-0871-3. PubMed PMID: 26673754; PubMed Central PMCID: PMC4704540. 2: Bourge RC, Tapson VF, Safdar Z, Benza RL, Channick RN, Rosenzweig EB, Shapiro S, White RJ, McSwain CS, Gotzkowsky SK, Nelsen AC, Rubin LJ. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. Cardiovasc Ther. 2013 Feb;31(1):38-44. doi: 10.1111/1755-5922.12008. PubMed PMID: 22970909; PubMed Central PMCID: PMC3561685. 3: Wang SS, Zeng YL, Zhang WW, Dong SL. A snake venom peptide with the contrary effects on rat stomach fundus and guinea pig ileum. Pharmazie. 2010 May;65(5):384-6. PubMed PMID: 20503934. 4: Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med. 2009 Mar;50(3):444-53. doi: 10.2967/jnumed.108.058602. Epub 2009 Feb 17. PubMed PMID: 19223402. 5: Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, Kharbanda S, Reimer C, Manfredi M, Dickerson WM, Kalluri R. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J Biol Chem. 2001 Aug 24;276(34):31959-68. Epub 2001 Jun 8. PubMed PMID: 11399763. 6: Kanda S, Kuzuya M, Ramos MA, Koike T, Yoshino K, Ikeda S, Iguchi A. Matrix metalloproteinase and alphavbeta3 integrin-dependent vascular smooth muscle cell invasion through a type I collagen lattice. Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):998-1005. PubMed PMID: 10764664. 7: Nanda NK, Sercarz E. A truncated T cell receptor repertoire reveals underlying immunogenicity of an antigenic determinant. J Exp Med. 1996 Sep 1;184(3):1037-43. PubMed PMID: 9064321; PubMed Central PMCID: PMC2192783. 8: Benelli R, Adatia R, Ensoli B, Stetler-Stevenson WG, Santi L, Albini A. Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy. Oncol Res. 1994;6(6):251-7. PubMed PMID: 7532474. 9: Carreno BM, Koenig S, Coligan JE, Biddison WE. The peptide binding specificity of HLA class I molecules is largely allele-specific and non-overlapping. Mol Immunol. 1992 Sep;29(9):1131-40. PubMed PMID: 1379681. 10: Melchiori A, Albini A, Ray JM, Stetler-Stevenson WG. Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment. Cancer Res. 1992 Apr 15;52(8):2353-6. PubMed PMID: 1313744. 11: Cibotti R, Kanellopoulos JM, Cabaniols JP, Halle-Panenko O, Kosmatopoulos K, Sercarz E, Kourilsky P. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):416-20. PubMed PMID: 1370355; PubMed Central PMCID: PMC48248. 12: Shapira-Nahor O, Golding H, Vujcic LK, Resto-Ruiz S, Fields RL, Robey FA. CD4-derived synthetic peptide blocks the binding of HIV-1 GP120 to CD4-bearing cells and prevents HIV-1 infection. Cell Immunol. 1990 Jun;128(1):101-17. PubMed PMID: 1971526. 13: Yang CY, Lee FS, Chan L, Sparrow DA, Sparrow JT, Gotto AM Jr. Determination of the molecular mass of apolipoprotein B-100. A chemical approach. Biochem J. 1986 Nov 1;239(3):777-80. PubMed PMID: 3827828; PubMed Central PMCID: PMC1147355. 14: Shastri N, Gammon G, Miller A, Sercarz EE. Ia molecule-associated selectivity in T cell recognition of a 23-amino-acid peptide of lysozyme. J Exp Med. 1986 Sep 1;164(3):882-96. PubMed PMID: 2427637; PubMed Central PMCID: PMC2188378. 15: Shastri N, Gammon G, Horvath S, Miller A, Sercarz EE. The choice between two distinct T cell determinants within a 23-amino acid region of lysozyme depends on their structural context. J Immunol. 1986 Aug 1;137(3):911-5. PubMed PMID: 2424989. 16: Manca F, Clarke JA, Miller A, Sercarz EE, Shastri N. A limited region within hen egg-white lysozyme serves as the focus for a diversity of T cell clones. J Immunol. 1984 Oct;133(4):2075-8. PubMed PMID: 6206149.